| Venclexta (venetoclax) / Roche, AbbVie |
PS-CLL-002, NCT04754035: Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 2a | 31 | Europe | Venetoclax, Imbruvica Oral Product | Paolo Ghia | Chronic Lymphocytic Leukemia | 07/18 | 09/25 | | |
MOONSHOT, ACTRN12625000387426: CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab |
|
|
| Not yet recruiting | 2 | 38 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) | Chronic Lymphocytic Leukaemia | | | | |
AETHER, ACTRN12625000732482: CLL12 - An ALLG phase II trial of venetoclax treatment with epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma |
|
|
| Not yet recruiting | 2 | 100 | | | Australasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group | Chronic Lymphocytic Leukemia, small lymphocytic lymphoma | | | | |
ACTRN12619001655134p: A study investigating different combinations of Cytarabine, Midistaurin, Pracinostat and Venetoclax in elderly patients with Acute Myeloid Leukaemia to extend remission. |
|
|
| Not yet recruiting | 2 | 308 | | | The Australasian Leukaemia and Lymphoma Group, Medical Research Future Fund (MRFF) | Acute Myeloid Leukaemia | | | | |
ACTRN12623000900617: AMLM28 Platform Trial - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT) |
|
|
| Not yet recruiting | 2 | 400 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) | Acute Myeloid Leukaemia | | | | |
ACTRN12623000851662: ALLG AMLM28/D1: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - Domain 1 |
|
|
| Withdrawn | 2 | 50 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) | Acute Myeloid Leukaemia | | | | |
ACTRN12619000746134: A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia |
|
|
| Recruiting | 2 | 32 | | | Alfred Hospital, Alfred Hospital | Acute Myeloid Leukemia | | | | |
AMLM22/D2, ACTRN12619000280101: -The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC). |
|
|
| Recruiting | 2 | 75 | | | Australian Leukaemia and Lymphoma Group (ALLG), Australian Leukaemia and Lymphoma Group (ALLG) | Acute Myeloid Leukaemia (AML) | | | | |
ACTRN12623000640606: CLL08 - A study to evaluate the efficacy of venetoclax/rituximab (VenR) re-treatment in relapsed/refractory Chronic Lymphocytic Leukaemia (CLL) patients with disease progression following VenR as their last line of therapy. |
|
|
| Recruiting | 2 | 80 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) | Chronic Lymphocytic Leukaemia | | | | |
NCT01994837: A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) |
|
|
| Completed | 2 | 32 | NA | ABT-199, ABT-199 also known as venetoclax | AbbVie, Genentech, Inc. | Acute Myelogenous Leukemia, AML, Acute Myeloid Leukemia | 12/14 | 12/14 | | |
CONTRALTO, NCT02187861 / 2014-000576-26: A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) |
|
|
| Completed | 2 | 163 | Canada, US, Europe, RoW | Venetoclax, GDC-0199, ABT-199, Bendamustine, Levact, Rituximab, MabThera, Rituxan | Hoffmann-La Roche, AbbVie | Follicular Lymphoma | 09/16 | 03/18 | | |
|
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens |
|
|
| Ongoing | 2 | 70 | Europe | obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro | HOVON Foundation, Dutch Cancer Society, Roche | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 66 | Europe | Bendamustine, GA101, Obinutuzumab, ABT-199, Venetoclax, GDC-0199 | German CLL Study Group, Hoffmann-La Roche, AbbVie | Chronic Lymphocytic Leucemia | 12/24 | 12/24 | | |
|
2016-004707-32: Clinical trial with Ibrutinib and Venetoclax for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Studio Clinico con Ibrutinib e Venetoclax per pazienti con Leucemia Linfatica Cronica Recidivante o Refrattaria |
|
|
| Ongoing | 2 | 31 | Europe | VENETOCLAX, [ABT-199], Film-coated tablet | OSPEDALE SAN RAFFAELE, Abbvie | Relapsed or Refractory Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica Recidivante o Refrattaria, Chronic Lymphocytic Leukemia relapsed or refractory to previous treatments Leucemia Linfatica Cronica ricaduta o non responsiva ai trattamenti precedenti, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2016-002599-29: A trial evaluating treatment with ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) |
|
|
| Ongoing | 2 | 230 | Europe | venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, ibrutinib, Tablet, Capsule, hard, Venclyxto, Imbruvica | HOVON Foundation, AbbVie, Janssen | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare |
|
|
| Not yet recruiting | 2 | 130 | Europe | Venclyxto, Film-coated tablet, Venclyxto | Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l. | Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 24 | Europe, US | Tafasitamab, MOR208, MOR00208, Idelalisib, Zydelig; GS-1101 or CAL-101, Venetoclax, Venclexta, Venclyxto; ABT-199 | MorphoSys AG | Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 11/18 | 12/21 | | |
|
|
|
2018-001475-20: Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO PREVENE (PREemptive Venetoclax) trial Traitement préemptif par Vénétoclax pour les patients atteints d’une LLC de stade A de haut risque, une étude de phase II du groupe FILO PREVENE (PREemptive VENEtoclax) |
|
|
| Not yet recruiting | 2 | 82 | Europe | venclyxto, ABT-199, Tablet, Venclyxto | FILO, Abbvie | Chronic lymphoid leukemia leucémie lymphoide chronique, High risk Binet stage A untreated CLL patients Patients atteints d’une LLC non précédemment traités, de stade A de Binet et à haut risque évolutif, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
V-VCD, ACTRN12618001085268: A trial of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) as induction therapy for newly diagnosed myeloma patients |
|
|
| Completed | 2 | 45 | | | Alfred Health, Abbvie | multiple myeloma | | | | |
NCT03785184 / 2018-003287-31: A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy |
|
|
| Withdrawn | 2 | 0 | Europe, Canada, US, RoW | venetoclax, ABT-199, lenalidomide, Revlimid, dexamethasone | AbbVie, Genentech, Inc., Celgene Corporation | Multiple Myeloma | 08/19 | 08/19 | | |
| Completed | 2 | 136 | Europe | Atezolizumab, Tecentriq, Obinutuzumab, Gazyvaro, Venetoclax, Venclyxto | The Lymphoma Academic Research Organisation | Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue | 09/19 | 08/22 | | |
NCT02677324: Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia |
|
|
| Completed | 2 | 33 | US | ABT199, Venetoclax | Dana-Farber Cancer Institute, AbbVie | Waldenstrom Macroglobulinemia | 02/20 | 02/22 | | |
| Terminated | 2 | 22 | Europe | Venetoclax, ABT-199/GDC-0199 | Fondazione Italiana Linfomi - ETS | T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | 03/20 | 02/23 | | |
NCT03045328: Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL |
|
|
| Completed | 2 | 22 | US | Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta | Steven E. Coutre | Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | 05/20 | 08/21 | | |
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia |
|
|
| Not yet recruiting | 2 | 40 | Europe | Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax) | Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG | Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04] | | | | |
NCT03567616 / 2017-004232-11: A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma |
|
|
| Terminated | 2 | 8 | Europe, US | Venetoclax, ABT-199, GDC-0199, Venclexta, Pomalidomide, Pomalyst, Dexamethasone | AbbVie, Celgene | Multiple Myeloma | 06/20 | 06/20 | | |
2020-001102-29: Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA) |
|
|
| Ongoing | 2 | 70 | Europe | Dexamethasone, Prevenar 13, Film-coated tablet, Tablet, Suspension for injection, Solution for injection, Venclyxto, Dexamethasone, Prevenar 13, Pneumovax | Department of Internal Medicine Vejle Hospital, Region of Southern Denmark | Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04] | | | | |
2019-004337-17: Behandeling van chronische lymfatische leukemie met venetoclax en acalabrutinib bij terugkeer van de ziekte na eerdere behandeling met venetoclax in combinatie met immuuntherapie Retreatment of CLL with venetoclax and acalabrutinib after relapse after first line venetoclax treatment combined with immunotherapy for chronic lymphocytic leukemia (CLL or SLL) |
|
|
| Ongoing | 2 | 60 | Europe | venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, Acalabrutnib, Tablet, Capsule, hard, Venclyxto | HOVON Foundation, AbbVie B.V., AstraZeneca BV | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
Veronica, NCT03584009 / 2017-005118-74: A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy |
|
|
| Terminated | 2 | 103 | Europe, Canada, US, RoW | Venetoclax, Fulvestrant | Hoffmann-La Roche, F. Hoffmann-La Roche Ltd | Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer | 08/20 | 05/21 | | |
2020-000273-24: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study |
|
|
| Ongoing | 2 | 186 | Europe | Venclyxto, Cytarabine, Daunorubicin, Gemtuzumab Ozogamicin, Tablet, Solution for injection/infusion, Powder for injection, Powder for concentrate for solution for infusion, Venclyxto | University of Birmingham, Cancer Research UK, AbbVie | Acute Myeloid Leukaemia, Acute Myeloid Leukaemia, Diseases [C] - Cancer [C04] | | | | |
NCT01889186 / 2012-004027-20: A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion |
|
|
| Completed | 2 | 158 | Europe, Canada, US, RoW | ABT-199 (Main Cohort), Venetoclax, GDC-0199, ABT-199 (Safety Expansion Cohort) | AbbVie, Genentech, Inc. | Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow | 10/20 | 12/20 | | |
|
|
|
|
|
|
|
|
|
2020-002297-26: Phase II study on Venetoclax (VEN) plus Decitabine (DEC) (VEN-DEC) for elderly (=60 <75years) patients with newly diagnosed Acute Myeloid Leukemia (AML) elegible for allogeneic Stem Cell Transplantation (allo-SCT) Studio di Fase II su Venetoclax (VEN) e Decitabine (DEC) (VEN-DEC) per pazienti anziani (=60 - <75 anni) con Leucemia Acuta Mieloide di nuova diagnosi (LAM) eleggibili per Trapianto Allogenico di Cellule Staminali Emopoietiche (allo-SCT) |
|
|
| Ongoing | 2 | 100 | Europe | Venclyxto, DACOGEN, [ABT-199], [DACOGEN], Tablet, Powder and solvent for solution for injection, Venclyxto, DACOGEN | GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA, Abbvie, Janssen | allogeneic transplantation in CR / Cri / MLFS condition trapianto allogenico in condizione di CR/Cri/MLFS, allogeneic transplantation in CR / Cri / MLFS condition trapianto allogenico in condizione di CR/Cri/MLFS, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 323 | Europe, US, RoW | ibrutinib, venetoclax, Placebo | Pharmacyclics LLC., Janssen Research & Development, LLC | Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 11/20 | 03/24 | | |
|
|
|
|
|
|
| Active, not recruiting | 2 | 37 | RoW | ABT-199, Ibrutinib | Peter MacCallum Cancer Centre, Australia | Mantle Cell Lymphoma | 11/20 | 06/25 | | |
|
|
NCT03755947: Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 3 | RoW | Ibrutinib, Imbruvica, Obinutuzumab, Gazyva, Venetoclax, Venclexta | Grupo Cooperativo de Hemopatías Malignas | B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis) | 12/20 | 02/21 | | |
| Not yet recruiting | 2 | 45 | Europe | Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi | Oslo University Hospital, Oslo University Hospital | Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 46 | Europe | Bendamustine, Obinutuzumab, GA101, Gazyvaro, Acalabrutinib, ACP-196, Calquence, Venetoclax, ABT-199, Venclyxto | German CLL Study Group | Chronic Lymphoid Leukemia | 02/21 | 09/23 | | |
| Completed | 2 | 12 | US | Laboratory Biomarker Analysis, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | City of Hope Medical Center, National Cancer Institute (NCI) | Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | 04/21 | 07/23 | | |
Zella 202, NCT03969420: Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy |
|
|
| Terminated | 2 | 11 | US | Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol) | Sumitomo Pharma America, Inc. | Acute Myeloid Leukemia (AML) | 04/21 | 05/21 | | |
PrE0403, NCT03113422: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy |
|
|
| Completed | 2 | 56 | US | Induction Venetoclax, GDC-0199, ABT-199, RO5537382, Maintenance Venetoclax | PrECOG, LLC., Genentech, Inc. | Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade | 05/21 | 01/23 | | |
2017-005118-74: A Study to Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer who Experienced Disease Recurrence or Progression During or after CDK4/6Inhibitor Therapy |
|
|
| Not yet recruiting | 2 | 105 | Europe | Venetoclax, Faslodex, RO5537382, RO3208209, Film-coated tablet, Solution for injection, Faslodex | F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Estrogen receptor-positive (ER+)/human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer (MBC), Locally advanced or metastatic breast cancer is breast cancer that has spread beyond the breast and continues to grow locally or spread to other parts of the body (metastatic), Diseases [C] - Cancer [C04] | | | | |
2020-004910-37: Study to compare the efficacy and safety of the combinaison of venetoclax+ibrutinib in patients with untreated mantle cell lymphoma |
|
|
| Not yet recruiting | 2 | 194 | Europe | ibrutinib, venetoclax, ABT - 199, Capsule, hard, Tablet, Imbruvica, Venclyxto | LYSARC, Janssen Pharmaceutica NV, Abbvie Inc | Untreated mantle cell lymphoma, Untreated mantle cell lymphoma, Diseases [C] - Cancer [C04] | | | | |
2020-004409-30: Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia Trattamento con venetoclax consolidato con ibrutinib e rituximab per aumentare possibilità di malattia minima residua in paziente con leucemia linfatica cronica |
|
|
| Not yet recruiting | 2 | 55 | Europe | venclyxto, [venclyxto], Modified-release tablet, Venclyxto | OSPEDALE SAN RAFFAELE, AbbVie | Previously Untreated Chronic Lymphophatic Leukaemia Leucemia Linfatica Cronica non precedentemente trattata, Previously untreated low-risk blood cancer Tumore del sangue a basso rischio, non precedentemente trattato, Diseases [C] - Cancer [C04] | | | | |
NCT04424147: Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML |
|
|
| Completed | 2 | 96 | RoW | HVA Regimens as Salvage Treatment | Nanfang Hospital of Southern Medical University, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Maoming People's Hospital, Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Shenzhen Hospital, Southern Medical University, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, The First People's Hospital of Chenzhou, Peking University Shenzhen Hospital, Zhongshan City People's Hospital | Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia, Salvage Treatment, HVA Regimen | 06/21 | 06/22 | | |
2020-005515-51: Tamoxifen and Venetoclax in R/R DLBCL Tamoxifen en Venetoclax in R/R DLBCL |
|
|
| Ongoing | 2 | 6 | Europe | Film-coated tablet, Venclyxto, Tamoxifen | Medical University Medical Center Groningen, University Medical Center Groningen | relapsed/refractory Diffuse Large B-cell Lymphoma recidiverend / refractair diffuus grootcellig B-cellymfoom, lymphoma lymfoom kanker, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
Vision HO141, NCT03226301: A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations |
|
|
| Active, not recruiting | 2 | 230 | Europe | Ibrutinib + Venetoclax 15 cycles, Ibrutinib until progression/relapse, Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles | Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group | Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission | 06/21 | 06/26 | | |
NCT03943342: Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance |
|
|
| Withdrawn | 2 | 0 | NA | Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta | Kerry Rogers, Janssen Research & Development, LLC | Chronic Lymphocytic Leukemia, Loss of Chromosome 17p | 07/21 | 07/21 | | |
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL |
|
|
| Completed | 2 | 141 | Europe | Venetoclax, Venclyxto (commercial name) | Fondazione Italiana Linfomi - ETS, AbbVie | Lymphoma, Mantle-Cell | 07/21 | 10/25 | | |
| Completed | 2 | 77 | Europe | Venetoclax, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia | 09/21 | 05/23 | | |
2020-006114-20: Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who are ineligible or unresponsive to intensive chemotherapy. Studio volto a valutare l'efficacia di un trattamento di associazione (decitabina e venetoclax) in pazienti affetti da Leucemia Mieliode Acuta che non sono idonei o non rispondono alla chemioterapia intensiva. |
|
|
| Not yet recruiting | 2 | 101 | Europe | VENCLYXTO 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PE/PCTFE-ALU)- 14 (7X2) COMP, Venclyxto 100 mg compresse rivestite con film, [NA], Film-coated tablet | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Fondazione Gimema Franco Mandelli Onlus, AbbVie Srl | Acute Myeloid Leukemia secondary to myeloproliferative neoplasms Leucemia Mieloide Acuta secondaria a neoplasie mieloproliferative, Secondary acute myeloid leukemia (AML) is an aggressive cancer caused by the uncontrolled multiplication of one of the immature cells (granulocytes) present in the bone marrow. La leucemia mieloide acuta secondaria (Lma) è un tumore aggressivo causato dalla moltiplicazione incontrollata di una delle cellule immature (granulociti) presenti nel midollo osseo., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 22 | Europe | Venetoclax, GA-101, Obinutuzumab, Gazyvaro | Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG | Lymphoma, Large B-Cell, Diffuse | 10/21 | 10/21 | | |
NCT04146038: Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease |
|
|
| Completed | 2 | 5 | US | Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Salsalate, Disalcid, Mono-Gesic, o-Salicylsalicylic Acid, Salflex, Salicylsalicylic Acid, Salsitab, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Rutgers, The State University of New Jersey, National Cancer Institute (NCI) | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | 10/21 | 10/22 | | |
2020-002622-87: A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemia |
|
|
| Not yet recruiting | 2 | 120 | Europe | Benlysta 200 mg Injektionslösung im Fertigpen, n.a., Injection, Benlysta 200 mg Injektionslösung im Fertigpen Benlysta 200 mg Injektionslösung in einer Fertigspritze | University Hospital Tuebingen, GlaxoSmithKline | Refractory or relapsed chronic lymphocytic leukemia, Refractory or relapsed chronic lymphocytic leukemia, Diseases [C] - Cancer [C04] | | | | |
2019-004613-14: Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of minimal residual disease in patients with untreated chronic lymphocytic leukemia Badanie kliniczne prowadzone celem oceny skuteczności terapii kombinacją leków o nazwie wenetoklaks i rytuksymab dostosowanej do stanu minimalnej choroby resztkowej u pacjentów z do tej pory nieleczoną przewlekłą białaczką limfocytową |
|
|
| Not yet recruiting | 2 | 103 | Europe | Venetoclax, Rituximab, Film-coated tablet, Concentrate for solution for infusion, Venclyxto, MabThera | POLISH ADULT LEUKEMIA GROUP, AbbVie, Inc. | Chronic lymphocytic leukemia Przewlekła białaczka limfocytowa, Chronic lymphocytic leukemia is a type of tumor that affects lymphocytes and lymph nodes. In CLL, lymphocytes are produced faster and live longer, which is why their number in the blood is too large. Przewlekła białaczka limfocytowa jest rodzajem nowotworu oddziałującym na limfocyty i węzły chłonne. W PBL limfocyty są wytwarzane szybciej i żyją dłużej, dlatego ich liczba we krwi jest zbyt duża., Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 14 | Europe, US, RoW | Venetoclax, ABT-199, GDC-0199, Venclexta®, Venclyxto®, Ibrutinib, Imbruvica® | AbbVie | Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer | 11/21 | 11/21 | | |
2021-003910-38: A study to test how the investigational drug tamibarotene works in combination with venetoclax and azacitidine to treat acute myeloid leukemia in untreated patients not eligible for standard therapy |
|
|
| Not yet recruiting | 2 | 95 | Europe | Tamibarotene, Venclyxto, Azacitidine, -, Tablet, Film-coated tablet, Powder for suspension for injection, Venclyxto | Syros Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc. | RARA-positive acute myeloid leukemia, Untreated adult patients with acute myeloid leukemia who have high levels of the RARA biomarker in their blood, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2021-002361-17: Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients suffering from Acute Myeloid Leukemia with NPM1 mutation. Studio volro a valutare l'efficacia della combinazione dei due farmaci, Venetoclax ed Azacitidina, sul trattamento di pazienti affetti da Leucemia Mieloide Acuta con mutazione di NPM1. |
|
|
| Not yet recruiting | 2 | 35 | Europe | Azacitidina, Venclyxto 100 mg compresse rivestite con film, [NA], Powder for suspension for injection, Film-coated tablet, PEGINTRON - 100 MCG POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE IN CARTUCCE A DUE SCOMPARTI IN 4 PENNE PRERIEMPITE + 4 AGHI + 8 TAMPONI USO SOTTOCUTANEO | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, ABBVIE S.r.l., Fondazione GIMEMA Franco Mandelli Onlus | Acute Myeloid Leukemia with NPM1 mutation. Leucemia Mieloide Acuta con mutazione NPM1., Disease that develops in the bone marrow and progresses quickly. If immature cells in the marrow, the corpuscular part of the blood, undergo mutations and become adults, AML is born. Malattia che si sviluppa nel midollo osseo e progredisce velocemente. Se le cellule immature nel midollo, la parte corpuscolata del sangue, subiscono mutazioni diventando adulte, si origina la LMA., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT04752527: Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features |
|
|
| Unknown status | 2 | 42 | RoW | venetoclax combined with decitabine, combination of venetoclax plus decitabine with or without sorafenib | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia, Adult | 12/21 | 12/22 | | |
2020-005866-32: A study to assess the efficacy of Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy to elderly patients with acute myeloid leukemia in first remission Etude évaluant l’efficacité de l’association Venetoclax + Cytarabine versus Idarubicine + Cytarabine en traitement de post-rémission chez des patients âgés en première rémission de Leucémie Aigue Myéloblastique |
|
|
| Not yet recruiting | 2 | 134 | Europe | Venclyxto, ABT-199, Tablet, VENCLYXTO | FILO, ABBVIE, FILO | elderly patients (> = 60 years) with Acute Myeloid Leukemia Patients âgés de 60 ans et plus, atteints d'une Leucémie Aigue Myéloïde, elderly patients (> = 60 years) with Acute Myeloid Leukemia Patients âgés de 60 ans et plus, atteints d'une Leucémie Aigue MyéloïdeLeucémie Aigue Myéloïde, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2020-005023-36: Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) |
|
|
| Not yet recruiting | 2 | 33 | Europe | TBD, Vidaza, Venclyxto | Akershus University Hospital, Norwegian Reserarch Council | Acute myeloid leukemia and severe myelodysplastic syndrome and chronic myelomonocytic leukemia, Acute myeloid leukemia and severe myelodysplastic syndrome and chronic myelomonocytic leukemia, Diseases [C] - Cancer [C04] | | | | |
NCT02141282: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy |
|
|
| Completed | 2 | 127 | US | Venetoclax, ABT-199, VENCLEXTA® | AbbVie, Roche-Genentech | Chronic Lymphocytic Leukemia | 12/21 | 12/21 | | |
|
|
|
| Completed | 2 | 41 | Europe | ibrutinib, obinutuzumab, venetoclax | University of Ulm, German CLL Study Group, Roche Pharma AG, Janssen-Cilag Ltd., AbbVie | Leukemia, Lymphocytic, Chronic | 01/22 | 03/22 | | |
|
|
NCT03766763: Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A |
|
|
| Active, not recruiting | 2 | 82 | Europe | Venetoclax | French Innovative Leukemia Organisation | Chronic Lymphoid Leukemia | 01/22 | 04/30 | | |
NCT04477486: Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma |
|
|
| Completed | 2 | 13 | Japan | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclexta, GDC-0199, Venclyxto | AbbVie | Mantle Cell Lymphoma (MCL) | 02/22 | 05/25 | | |
2020-005461-14: Study of Acute myelogenic Leukemia (AML) treatment for patients who can not recieve intensiv chemotherapy combining standard treatment (Azacitidin ) with study medicine(low dose Venetoclax) for better responce and we will look at effect of medicines on leukemic cells and possible resistence developement to help find new ways for treatment Studie om behandling av Akutt Myelogen Leukemi(AML) med kombinasjon av Standard behandling (Azacytidine) med studiemedisin(Lavdose Venetoclax )hos pasienter som ikke kan få kraftig cellgiftbehandling |
|
|
| Ongoing | 2 | 117 | Europe | VENETOCLAX, Tablet, Venclyxto | Righospitalet, Rigshospitalet, Rigshospitalet, , NA | Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will use study medicine (low dose Venetoclax)in combination with standard treatment (Azacitidine) for better responce and survival and examine mechanism for drug sensitivity and resistence Akutt Myelogen Leukemi (AML) er agressiv type leukemia og behandlingen er ufordrende hos pasienter som ikke kan få intensiv cellgift behandling eller fått tilbakefall etter intensiv cellgift kurenI denne studien vil vi kombinere studiemedisin (lav dose Venetoclax )med Standard behandling(Azacitidin)for bedre responce og overlevelseVi vil også undersøkre mekanismer for medikament responce og resistence utvikling, AML is agressiv type blood cancer which is common in elderly and is challenging to treat specialy i patient who can not recieve intensiv chemotherapy or get relapsed disease after such therapy , AML er aggressiv type blodkreft vanligvis rammer eldre det er utfordrende å behandle spesielt hos pasienter som ikke kan få intensiv cellegift behandling eller fått tilbakefall etter slik behandling, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
UTX-TGR-208, NCT04016805: Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax |
|
|
| Terminated | 2 | 41 | US | Ublituximab, TG-1101, Umbralisib, TGR-1202, Ibrutinib, Imbruvica, Venetoclax, Venclexta, Acalabrutinib Oral Capsule, Calquence | TG Therapeutics, Inc. | Chronic Lymphocytic Leukemia | 05/22 | 05/22 | | |
2020-004772-18: A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Estudio de la farmacocinética, la seguridad y la eficacia de ASTX727 en combinación con venetoclax en casos de LMA |
|
|
| Suspended | 2 | 100 | Europe | ASTX727 (decitabine and cedazuridine), Venetoclax, ASTX727, Tablet, Film-coated tablet, Venclyxto | Astex Pharmaceuticals, Inc., Astex Pharmaceuticals, Inc. | Acute Myeloid Leukemia (AML) Leucemia mieloide aguda (LMA), Acute Myeloid Leukemia (AML) Leucemia mieloide aguda (LMA), Diseases [C] - Cancer [C04] | | | | |
NCT05282719: Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults |
|
|
| Enrolling by invitation | 2 | 33 | RoW | venetoclax combined with azacitidine, combination of venetoclax plus azacitidine | The First Affiliated Hospital of Soochow University | Myelodysplastic/Myeloproliferative Neoplasms, Adult | 08/22 | 02/23 | | |
ChiCTR1900025374: Maintenance therapy with low-dose decitabine and venetoclax after allogeneic stem cell transplantation for patients with acute leukemia/myelodysplastic syndrome: a non-randomised, open-label, phase II study |
|
|
| Recruiting | 2 | 30 | | Decitabine combined with Venetoclax | Tianjin First Central Hospital; Tianjin First Central Hospital, Self-raised | Acute Myeloid Leukemia | | | | |
| Completed | 2 | 164 | Europe, Canada, US | Pevonedistat, TAK-924, MLN4924, Venetoclax, Azacitidine | Takeda | Acute Myeloid Leukemia (AML) | 09/22 | 10/25 | | |
NCT05084027: Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT |
|
|
| Recruiting | 2 | 50 | RoW | venetoclax combining with fludarabine and melphalan | First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial People's Hospital, The affiliated people's hospital of Ningbo University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Hospital of Zhejiang University, The First Affiliated Hospital of Zhejiang Chinese Medical University | Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation | 09/22 | 09/24 | | |
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age |
|
|
| Completed | 2 | 33 | US | Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan | PrECOG, LLC., Genentech, Inc. | Mantle Cell Lymphoma | 10/22 | 07/24 | | |
ChiCTR2100051119: A prospective, single-arm, multicenter, phase 2 clinical study of the efficacy and safety of VAA regimen (venetoclax combined with azacitidine, cytarabine) in the treatment of newly diagnosed myelodysplastic syndrome-transformed leukemia patients |
|
|
| Recruiting | 2 | 31 | | VAA chemotherapy regimen | The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine, Project funding | Acute myeloid leukemia （MDS-drived） | | | | |
| Active, not recruiting | 2 | 100 | Europe | Venetoclax and Decitabine | Gruppo Italiano Trapianto di Midollo Osseo, Abbvie, Janssen | Acute Myeloid Leukemia | 02/23 | 06/25 | | |
NCT05048615: Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML |
|
|
| Completed | 2 | 15 | RoW | Venetoclax 100 MG, Venclexta, Itraconazole capsule, Azacitidine Injection, Vidaza | Hospital Universitario Dr. Jose E. Gonzalez | AML | 01/23 | 01/23 | | |
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms. |
|
|
| Ongoing | 2 | 150 | Europe | Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten | University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV | Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04] | | | | |
2022-002435-66: Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leukemia undergoing allogeneic blood stem cell transplantation Studie zur Bewertung der Sicherheit und Wirksamkeit von Venetoclax zusätzlich zu einer Standard-Konditionierung bei Patienten mit bestimmten Formen von Leukämie, die sich einer allogenen Blutstammzelltransplantation unterziehen |
|
|
| Not yet recruiting | 2 | 38 | Europe | Film-coated tablet, , Venclyxto | Heinrich-Heine-Universität Düsseldorf represented by the Coordinating Investigator, AbbVie Deutschland GmbH & Co. KG, Medac GmbH, Eurocept International B.V. | Patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or secondary acute myeloid leukemia (sAML) before stem cell transplantation Patienten mit myelodysplastischem Syndrom (MDS), chronischer myelomonozytärer Leukämie (CMML) oder sekundärer akuter myeloischer Leukämie (sAML) vor Stammzelltransplantation, Patients with certain forms of leukemia before stem cell transplantation Patienten mit bestimmten Formen von Leukämie vor Stammzelltransplantation, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT04487106: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome |
|
|
| Completed | 2 | 21 | US | Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | 02/23 | 01/24 | | |
NCT05361057: Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients |
|
|
| Terminated | 2 | 20 | RoW | Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine | Institute of Hematology & Blood Diseases Hospital, China | Acute Myeloid Leukemia, Measurable Disease | 02/23 | 01/24 | | |
2021-002007-35: Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Étude évaluant le traitement par vénétoclax et vidaza (azacitidine) chez des patients atteints de leucémies myélomonocytaires chroniques de risque intermédiaire ou élevé |
|
|
| Not yet recruiting | 2 | 44 | Europe | Venclyxto, Vidaza, ABT-199, Film-coated tablet, Powder for suspension for injection, Venclyxto, Vidaza | Groupe Francophone des Myélodysplasies (GFM), AbbVie | Newly diagnosed, HMA-naïve, higher-risk (HR, defined as CPSS risk intermediate-2 or high) CMML patients Patients atteints de LMMC de risque élevé, nouvellement diagnostiqués, n'ayant jamais reçu d'hypométhylants, Newly diagnosed, HMA-naïve, higher-risk CMML patients Patients nouvellement diagnostiqués d'une LMMC de risque élevé n'ayant jamais reçu d'agents hypométhylants, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
CORAL, NCT05209308: Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL |
|
|
| Withdrawn | 2 | 42 | US | Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta | MEI Pharma, Inc., Kyowa Kirin, Inc. | CLL | 03/23 | 03/23 | | |
NCT04990778: Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma |
|
|
| Withdrawn | 2 | 0 | US | Eprenetapopt, APR-246, PRIMA-1MET, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | M.D. Anderson Cancer Center | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 03/23 | 03/23 | | |
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio. |
|
|
| Not yet recruiting | 2 | 78 | Europe | Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus | Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT05362942: Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 2 | 52 | NA | Venetoclax, Decitabine, Azacytidine, Cytarabine, Venetoclax (ABT-199, GDC-0199), Decitabine (Dacogen, 5-aza-2-deoxycytidine), Azacitidine (5-Azacytidine, Ladakamycin), Cytarabine (Cytarabine hydrochloride) | Beijing 302 Hospital | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease | 04/23 | 04/24 | | |
| Terminated | 2 | 20 | Europe | sabatolimab, MBG453, azacitidine, venetoclax | Novartis Pharmaceuticals | Myelodysplastic Syndrome (MDS) | 05/23 | 05/23 | | |
| Active, not recruiting | 2 | 45 | US | IBRUTINIB, Imbruvica, Venetoclax, Venclexta | Dana-Farber Cancer Institute, AbbVie, Pharmacyclics LLC. | Waldenstrom Macroglobulinemia, MYD88 Gene Mutation | 06/22 | 02/28 | | |
NCT05433532: Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients |
|
|
| Completed | 2 | 20 | RoW | Azacitidine, Venetoclax, Flumatinib | The First Affiliated Hospital of Soochow University | Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Mixed Phenotype Acute Leukemia | 04/24 | 04/24 | | |
| Not yet recruiting | 2 | 10 | Europe | Venclyxto, Venetoclax, Film-coated tablet, Venclyxto | Friedrich-Schiller-Universität Jena, Abbvie | Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2021-003248-26: Evaluation of efficacy and tolerability of the combination of venetoclax and azacitidine in comparison to standard of care intensive chemotherapy for treatment of fit patients with acute myeloid leukemia and mutation in NPM1 gene Vergleichende Untersuchung der Wirksamkeit und Verträglichkeit der Kombinationstherapie aus Venetoclax und Azacitidin zur Standardtherapie für die Behandlung von fitten Patienten mit akuter myeloischen Leukämie und Mutation im NPM1-Gen |
|
|
| Not yet recruiting | 2 | 146 | Europe | Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Gemtuzumab Ozogamicin, Mitoxantrone, ABT-199, Film-coated tablet, Powder for suspension for injection, Concentrate for concentrate for solution for infusion, Powder for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion | Technische Universität Dresden, AbbVie Deutschland GmbH & Co.KG, Technische Universität Dresden | Patients 18-70 years eligible for intensive therapy with newly diagnosed acute myeloid leukemia (AML) harboring an NPM1 mutation and no activating FLT3 mutation, Patients 18-70 years eligible for intensive therapy with newly diagnosed acute myeloid leukemia (AML) and mutation in NPM1 gene, Diseases [C] - Cancer [C04] | | | | |
ChiCTR2200061708: A prospective, single arm, multicenter study on the efficacy and safety of venetoclax+ HAG regimen for induction treatment in newly diagnosed adult Early T-cell precursor (ETP) acute lymphoblastic leukemia |
|
|
| Recruiting | 2 | 22 | | venetoclax combined with HAG regimen | The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Funding | Early T-cell precursor (ETP) acute lymphoblastic leukemia | | | | |
| Recruiting | 2 | 53 | RoW | QHRD107 capsule，Venclexta and Azacitidine, CDK9 inhibitors | Changzhou Qianhong Bio-pharma Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) | 02/25 | 05/25 | | |
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 23 | US | Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382 | Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH) | CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive | 06/22 | 04/26 | | |
NCT05513131: Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML |
|
|
| Recruiting | 2 | 30 | RoW | Venetoclax；Azacitidine；Homoharringtonine | The First Affiliated Hospital with Nanjing Medical University | Secondary Acute Myeloid Leukemia | 09/23 | 09/25 | | |
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma |
|
|
| Recruiting | 2 | 40 | US | Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc. | Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma | 04/26 | 04/26 | | |
NCT02397720: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Completed | 2 | 150 | US | Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Venetoclax, ABT-199, GDC-0199, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia | 10/23 | 10/23 | | |
|
NCT03467867: A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL |
|
|
| Active, not recruiting | 2 | 25 | US | Venetoclax, GDC-0199, ABT-199, Rituximab, Rituxan, Rituximab/Hyaluronidase Human, Rituxan Hycela | Georgetown University, Hackensack Meridian Health | Chronic Lymphocytic Leukemia | 12/26 | 12/26 | | |
| Terminated | 2 | 54 | Europe, US, RoW | Magrolimab, GS-4721, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486, Onureg | Gilead Sciences | Myeloid Malignancies | 03/24 | 03/24 | | |
| Recruiting | 2 | 27 | Europe | Decitabine, Dacogen, Venetoclax, Venclyxto, Venclexta | University Hospital Tuebingen | AML, MDS | 09/26 | 03/27 | | |
NCT03609593: Bendamustine/rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 2 | 42 | US | Bendamustine, Treanda, Venetoclax, ABT-199, Venclexta, Rituximab, Rituxan | Nicole Lamanna | Chronic Lymphocytic Leukemia | 02/26 | 12/26 | | |
ERADIC, NCT04010968: Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 120 | Europe | venetoclax and ibrutinib (I+VEN), FCR | French Innovative Leukemia Organisation, AbbVie, Janssen-Cilag Ltd. | Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy | 04/23 | 01/25 | | |
